Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial

Abstract

Intracoronary administration of BMCs is associated with a significant reduction of the occurrence of major adverse cardiovascular events after AMI. Large-scale studies are warranted to confirm the effects of BMC administration on mortality and morbidity in patients with AMIs.

Cardiac Repair Using Stem Cells Conditioned Media Based Therapy in a Rodent Model of Myocardial Infarction and Heart Failure

“…In animal models, these cellbased therapies have demonstrated effectiveness in reducing infarct size and ventricular dilatation, and improving myocardial function [24][25][26] . Similar results have been demonstrated in human models, however clinical translation is limited 8,13,19 . Primarily, the ideal source of human cardiomyocyte progenitors remains unidentified, though further understanding of the differentiation of embryonic stem cells and human induced pluripotent stem cells (HiPSCs) into cardiomyocytes is curbing this concern 27,28 .…”

“…human and animal models, to varying degrees of success [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] . In animal models, these cellbased therapies have demonstrated effectiveness in reducing infarct size and ventricular dilatation, and improving myocardial function [24][25][26] .…”

“…Infarction (REPAIR-AMI) that showed an initial result of increase in LVEF 37 , both used bone marrow derived MSC as the choice of stem cells. In regards to the acute presentation for more than 7 days, trials such as CArdiosphere-Derived aUtologous Stem CElls to reverse ventricUlar dySfunction (CADUCEUS) showed a significant decrease in the scar size and increase in viable myocardium at 6 and 12 months 17 it mainly used cardiosphere derived stem cells using resident cardiac stem cells.…”

Impact of Timing on Efficacy and Safetyof Intracoronary Autologous Bone Marrow Stem Cells Transplantation in Acute Myocardial Infarction: A Pooled Subgroup Analysis of Randomized Controlled Trials

“…The improved perfusion capacity might stimulate the endothelium to release nitric oxide, which exerted antiatherosclerotic functions and might counteract the process of restenosis development and atherosclerotic disease progression. 7,23 On the basis of these findings, we speculate that the improvement in coronary blood flow reserve might be one of the mechanisms responsible for the observed reduction in revascularization procedures in patients receiving BMSC transfer at 4 to 7 days post-AMI.…”

Stem Cell Therapy Combined with Myocardial Revascularization: A Pilot Study using the Harvest Technique

“…Stem cell therapy may represent the hope for those types of patients [1][2][3][4][5][6][7][8][9][10][11][12]. Several studies discussed this promising therapy with different techniques and routes including surgical transepicardial (intramyocardial injection) [1,[9][10][11][12], selective intracoronary artery infusion [2][3][4], percutaneous transfemoral endoventricular (catheter-based transendocardial injection) [5,6] or retrograde coronary venous [8]. Here in, we aimed to assess the usefulness of intra-myocardial autologous stem cell injection as a hybrid procedure with CABG compared to conventional CABG only in those patients with ischemic heart disease with non-viable or non-graftable myocardial segments.…”